Cinnamon extract suppresses tumor progression by modulating angiogenesis and the effector function of CD8+ T cells

Cancer Letters

Volumn 278, Issue 2, 2009, Pages 174-182

  Kwon, Ho Keun ^a   Jeon, Won Kyung ^b   Hwang, Ji Sun ^a   Lee, Choong Gu ^a   So, Jae Seon ^a   Park, Jin A ^a   Ko, Byoung Seob ^b   Im, Sin Hyeog ^a  

^a Gwangju Institute of Science and Technology (GIST)   (South Korea)

^b Korea Institute of Oriental Medicine (KIOM)   (South Korea)

Author keywords

Angiogenesis; Anti cancer effect; Cinnamon; Complementary and alternative medicine (CAM); Cytotoxic T cell

Indexed keywords

CINNAMON EXTRACT; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CD8+ T LYMPHOCYTE; CELL FUNCTION; CONTROLLED STUDY; CYTOTOXICITY; MALE; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CINNAMOMUM ZEYLANICUM; CYCLOOXYGENASE 2 INHIBITORS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PATHOLOGIC; PLANT EXTRACTS;

CINNAMOMUM VERUM;

EID: 64649105694     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2009.01.015     Document Type: Article

References (42)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., and Thun M.J. Cancer statistics, 2007. CA Cancer J. Clin. 57 (2007) 43-66
2. Cassileth B.R., Lusk E.J., Strouse T.B., and Bodenheimer B.J. Contemporary unorthodox treatments in cancer medicine. A study of patients, treatments, and practitioners. Ann. Intern. Med. 101 (1984) 105-112
3. Cassileth B.R. Complementary and alternative cancer medicine. J. Clin. Oncol. 17 (1999) 44
4. DiPaola R.S., Zhang H., Lambert G.H., Meeker R., Licitra E., Rafi M.M., Zhu B.T., Spaulding H., Goodin S., Toledano M.B., Hait W.N., and Gallo M.A. Clinical and biologic activity of an estrogenic herbal combination (PC-SPES) in prostate cancer. New Engl. J. Med. 339 (1998) 785-791
5. Buchanan D.R., White J.D., O'Mara A.M., Kelaghan J.W., Smith W.B., and Minasian L.M. Research-design issues in cancer-symptom-management trials using complementary and alternative medicine: lessons from the national cancer institute community clinical oncology program experience. J. Clin. Oncol. 23 (2005) 6682-6689
6. Meijerman I., Beijnen J.H., and Schellens J.H.M. Herb-drug interactions in oncology: focus on mechanisms of induction. Oncologist 11 (2006) 742-752
7. Tascilar M., de Jong F.A., Verweij J., and Mathijssen R.H.J. Complementary and alternative medicine during cancer treatment: beyond innocence. Oncologist 11 (2006) 732-741
8. Lee S.H., Lee S.Y., Son D.J., Lee H., Yoo H.S., Song S., Oh K.W., Han D.C., Kwon B.M., and Hong J.T. Inhibitory effect of 2′-hydroxycinnamaldehyde on nitric oxide production through inhibition of NF-[kappa]B activation in RAW 264.7 cells. Biochem. Pharmacol. 69 (2005) 791-799
9. Singh G., Maurya S., deLampasona M.P., and Catalan C.A.N. A comparison of chemical, antioxidant and antimicrobial studies of cinnamon leaf and bark volatile oils, oleoresins and their constituents. Food Chem. Toxicol. 45 (2007) 1650-1661
10. Lee J.-S., Jeon S.-M., Park E.-M., Huh T.-L., Kwon O.-S., Lee M.-K., and Choi M.-S. Cinnamate supplementation enhances hepatic lipid metabolism and antioxidant defense systems in high cholesterol-fed rats. J. Med. Food 6 (2003) 183-191
11. Matan N., Rimkeeree H., Mawson A.J., Chompreeda P., Haruthaithanasan V., and Parker M. Antimicrobial activity of cinnamon and clove oils under modified atmosphere conditions. Int. J. Food Microbiol. 107 (2006) 180-185
12. Khan A., Safdar M., Ali Khan M.M., Khattak K.N., and Anderson R.A. Cinnamon improves glucose and lipids of people with type 2 diabetes. Diab. Care 26 (2003) 3215-3218
13. Kim S.H., Hyun S.H., and Choung S.Y. Anti-diabetic effect of cinnamon extract on blood glucose in db/db mice. J. Ethnopharmacol. 104 (2006) 119-123
14. Qin B., Nagasaki M., Ren M., Bajotto G., Oshida Y., and Sato Y. Cinnamon extract (traditional herb) potentiates in vivo insulin-regulated glucose utilization via enhancing insulin signaling in rats. Diab. Res. Clin. Pract. 62 (2003) 139-148
15. Schoene N.W., Kelly M.A., Polansky M.M., and Anderson R.A. Water-soluble polymeric polyphenols from cinnamon inhibit proliferation and alter cell cycle distribution patterns of hematologic tumor cell lines. Cancer Lett. 230 (2005) 134-140
16. Kamei T., Kumano H., Iwata K., Nariai Y., and Matsumoto T. The effect of a traditional Chinese prescription for a case of lung carcinoma. J. Alternat. Complemen. Med. 6 (2000) 557-559
17. So J.-S., Kwon H.-K., Lee C.-G., Yi H.-J., Park J.-A., Lim S.-Y., Hwang K.-C., Jeon Y.H., and Im S.-H. Lactobacillus casei suppresses experimental arthritis by down-regulating T helper 1 effector functions. Mol. Immunol. 45 (2008) 2690
18. + adherent tumor cells. J. Immunol. Methods 217 (1998) 71
19. Vanderheyde N., Aksoy E., Amraoui Z., Vandenabeele P., Goldman M., and Willems F. Tumoricidal activity of monocyte-derived dendritic cells: evidence for a caspase-8-dependent, Fas-associated death domain-independent mechanism. J. Immunol. 167 (2001) 3565-3569
20. Gasparini G., Longo R., Sarmiento R., and Morabito A. Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents?. Lancet Oncol. 4 (2003) 605
21. Pugh C.W., and Ratcliffe P.J. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat. Med. 9 (2003) 677
22. Cuezva J.M., Krajewska M., de Heredia M.L., Krajewski S., Santamaria G., Kim H., Zapata J.M., Marusawa H., Chamorro M., and Reed J.C. The bioenergetic signature of cancer: a marker of tumor progression. Cancer Res. 62 (2002) 6674-6681
23. Semenza G.L. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 3 (2003) 721
24. Newman P.J., and Newman D.K. Signal transduction pathways mediated by PECAM-1: new roles for an old molecule in platelet and vascular cell biology. Arterioscler. Thromb. Vasc. Biol. 23 (2003) 953-964
25. Leahy K.M., Ornberg R.L., Wang Y., Zweifel B.S., Koki A.T., and Masferrer J.L. Cyclooxygenase-2 Inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res. 62 (2002) 625-631
26. Prlic M., Williams M.A., and Bevan M.J. Requirements for CD8 T-cell priming, memory generation and maintenance. Curr. Opin. Immunol. 19 (2007) 315
27. Glimcher L.H., Townsend M.J., Sullivan B.M., and Lord G.M. Recent developments in the transcriptional regulation of cytolytic effector cells. Nat. Rev. Immunol. 4 (2004) 900
28. Bergers G., and Benjamin L.E. Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer 3 (2003) 401
29. Rafii S., Lyden D., Benezra R., Hattori K., and Heissig B. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy?. Nat. Rev. Cancer 2 (2002) 826
30. Plate K.H., Breier G., Weich H.A., and Risau W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359 (1992) 845
31. Shweiki D., Itin A., Soffer D., and Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359 (1992) 843
32. Araki Y., Okamura S., Hussain S.P., Nagashima M., He P., Shiseki M., Miura K., and Harris C.C. Regulation of cyclooxygenase-2 expression by the Wnt and Ras pathways. Cancer Res. 63 (2003) 728-734
33. Tomozawa S., Tsuno N.H., Sunami E., Hatano K., Kitayama J., Osada T., Saito S., Tsuruo T., Shibata Y., and Nagawa H. Cyclooxygenase-2 overexpression correlates with tumour recurrence, especially haematogenous metastasis, of colorectal cancer. Br. J. Cancer 83 (2000) 324
34. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer 5 (2005) 263
35. Gajewski T.F., Meng Y., Blank C., Brown I., Kacha A., Kline J., and Harlin H. Immune resistance orchestrated by the tumor microenvironment. Immunol. Rev. 213 (2006) 131-145
36. + tumor-specific T cell clones derived from human melanoma-infiltrating lymphocytes in response to autologous tumor cells in vitro. Eur. J. Immunol. 24 (1994) 1966-1973
37. Zippelius A., Batard P., Rubio-Godoy V., Bioley G., Lienard D., Lejeune F., Rimoldi D., Guillaume P., Meidenbauer N., Mackensen A., Rufer N., Lubenow N., Speiser D., Cerottini J.-C., Romero P., and Pittet M.J. Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance. Cancer Res. 64 (2004) 2865-2873
38. + tumor-infiltrating T cells are deficient in perforin-mediated cytolytic activity due to defective microtubule-organizing center mobilization and lytic granule exocytosis. J. Immunol. 167 (2001) 5042-5051
39. + T cells. J. Immunol. 176 (2006) 6103-6111
40. Van Den Hove L.E., Van Gool S.W., Van Poppel H., Baert L., Coorevits L., Van Damme B., and Ceuppens J.L. Phenotype, cytokine production and cytolytic capacity of fresh (uncultured) tumour-infiltrating T lymphocytes in human renal cell carcinoma. Clin. Exp. Immunol. 109 (1997) 501-509
41. Nakagomi H. Lack of interleukin-2 (IL-2) expression and selective expression of IL-10 mRNA in human renal cell carcinoma. Int. J. Cancer 63 (1995) 366-371
42. Wu K.-M., and Farrelly J.G. Regulatory perspectives of type II prodrug development and time-dependent toxicity management: nonclinical pharm/tox analysis and the role of comparative toxicology. Toxicology 236 (2007) 1